
    
      An open-label Phase 1 study to evaluate the safety, tolerability, PK/PD and preliminary
      efficacy of HBM4003 combined with toripalimab in patients with advanced melanoma and other
      solid tumors.

      The study is composed of two part, part 1 will be approximately 31subjects and Part 2 will be
      approximately 30 subjects.
    
  